We invite you to join us for a special event in San Francisco on Thursday, May 8, featuring four of our top UQ alumni in North America who have succeeded in the areas of entrepreneurship and venture capital. The speakers will talk about their experiences, answer audience questions, and engage in what we hope will be a lively discussion.
The event will feature four successful UQ alumni, including:
- Dr Roslyn Brandon, Founding CEO of Immunexpress Inc.
- Dr Denver Dale, Founder and CEO of On-Point Capital LLC
- Dr Warren Hogarth, Partner, Sequoia Capital
- Dr Deborah Pascoe, Health Tech Startup Advisor, (Moderator)
The discussion will be followed by a networking reception. Further information on the event, including speaker bios, can be found below. We hope you will be able to join us!
With all good wishes,
The UQ North America office
THE UNIVERSITY OF QUEENSLAND
ALUMNI ON THE RISE RECEPTION
Featuring successful North American UQ alumni who have succeeded in venture capital and entrepreneurship
Thursday 8 May 2014
6:00pm - 8:00pm Reception and Registration
25th Floor, Hotel Nikko San Francisco
Nearest BART station: Powell Street
Map and Directions http://www.hotelnikkosf.com/map.aspx
RSVP TO ATTEND
Register attendance >
For more information:
Call: +1 202 495 3670 or +1-202-495-3671
Here are the short biographies of our speakers for this event.
Dr. Roslyn Brandon is the Founding CEO of Immunexpress Inc. based in Seattle, WA. The company has developed a range of new generation molecular diagnostics for the management of sepsis and hospital-acquired infections, with its first product launching in the US market in 2015. During her entrepreneurial career, she has raised more than US$30 million in equity capital and US$10 million in non-dilutive capital. Roz also serves as Director of the Board of The University of Queensland in America Foundation. She earned her BVSc (Hons I) (DVM-equivalent) and Ph.D. (Medicine) from the University of Queensland, and was a University Medalist for her MBA from the Queensland University of Technology.
Dr. Denver Dale is the founder and CEO of On-Point Capital LLC, an investment management firm that provides highly specialized investment services to significant investors. In this capacity, Denver sets overall strategy for the firm and leads investment platform design, development and execution. Current areas of interest include Non-Medical Biotech, Defence Tech and Australasian Innovation. Prior to forming OPC, Denver ran an elite investment unit within Goldman Sachs & Co. managing more than US$4 billion on behalf of a small number of significant investors. In addition, Denver has been the founder, director and CFO of several technology-enabled businesses where he designed and managed global operations, investor relations, client services and business development. Denver has a Ph.D. in biomedical sciences from Oxford University and a B.Sc. (Hons) in medical biology from the University of Queensland, Australia. He grew up on a farm west of Toowoomba. His professional profile can be found at http://www.linkedin.com/in/denverdale.
Dr Warren Hogarth is a Partner at Sequoia Capital, a leading Venture Capital firm in Silicon Valley, where he focuses on bioinformatics, SaaS, and consumer technology investments. He is a director of Silicon Valley Biosystems, FutureAdvisor, Comprehend Systems, & Guardant Health. He is also responsible for Sequoia’s investments in AssureRx, SunRun, Gigagen and a number of stealth companies. Prior to joining Sequoia Capital in 2008, Warren completed his PhD in Chemical Engineering from the University of Queensland in Australia, during which time he was a Fulbright Scholar at Princeton University and a Guest Scientist at the Fraunhofer Institute in Germany. In addition to his PhD, Warren has an MBA from Harvard Business School and a Bachelors in Engineering and BComm from The University of Queensland, Australia.
Dr Deborah Pascoe, who will be our moderator for the evening, is an experienced technology, operations, and strategy leader in established and early stage life science and medical device companies. After ten years at Genentech in R&D and Manufacturing, Deborah led Operations at 23andMe and now works with startup companies in health technology. She is known for developing effective, focused teams that deliver critical results in challenging situations. Deborah received her PhD in Chemical Engineering from Northwestern University in Chicago and her Bachelors in Engineering (Hons) from The University of Queensland, Australia. Her professional profile can be found at http://www.linkedin.com/in/deborahpascoe.